On November 24, 2024, Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (hereinafter referred to as " Hanx Biopharmaceuticals ") from Wuhan, Hubei, reported the company submitted a prospectus to the Hong Kong Stock Exchange, intending to list on the main board of Hong Kong through an IPO (Press release, HanX Biopharmaceuticals, NOV 25, 2024, View Source [SID1234655966]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hans Biotech , an innovative biotechnology company with proprietary expertise and experience in structural biology, translational medicine, and clinical development, is dedicated to discovering, developing, and commercializing first-in-class and/or best-in-class products for the precision treatment of cancer and autoimmune diseases, addressing global unmet medical needs. The company acquired an equity stake in Hangzhou Hans Biotech in 2017 and has since focused on proven therapeutic mechanisms.

As of November 18, 2024, Hans-Etienne has developed a pipeline of 10 drug candidates (eight in oncology and two in autoimmune disease in clinical or preclinical development) , including its core product HX009 (an independently developed PD-1/SIRPα bifunctional antibody fusion protein) , two key products HX044 and HX301, and seven preclinical-stage drug candidates, including antibody-drug conjugates, bsAbs, and mAbs, targeting the autoimmune and oncology markets. Hans-Etienne ‘s pipeline development strategy is based on validated targets and pathways, supported by molecules with unique target biology, translational evidence, clinical feasibility, and druggable structures. The company is positioned to provide next-generation immuno-oncology therapies, such as HX009, HX044, and HX016, to combat PD-1 resistance; first-in-class ADC molecule HX111, for the precision treatment of specific malignancies; and novel autoimmune therapies, such as the bsAb bifunctional antibodies HX035 and HX038.

Hansaitai ‘s core product, HX009, is an independently developed PD-1/SIRPα bifunctional antibody fusion protein. Phase I clinical trials for HX009 have been completed in Australia and China. The company is currently conducting two HX009 clinical programs in China: the HX009-I-01 China study (Phase Ib) for the treatment of advanced melanoma, and the HX009-II-02 China study (Phase I/II) for the treatment of R/R EBV+ non-Hodgkin’s lymphoma.

The two main products, HX301 and HX044, are in the clinical stage and focus on the treatment of cancer. HX301 is a multi-target kinase inhibitor targeting key pathways such as CSF1R, ARK5, FLT-3 and CDK4/6. Hans Aita has completed the Phase I clinical study of HX301 approved by the National Medical Products Administration, and plans to conduct a Phase II clinical study of HX301 in combination with temozolomide for the treatment of glioblastoma. HX044 is a novel dual-functional anti-CTLA-4 antibody SIRPα fusion protein designed to enhance the targeted efficacy of CTLA-4. Currently, the company is initiating a Phase I/IIa clinical study in Australia for the treatment of advanced solid tumor malignancies and has obtained the National Medical Products Administration’s acceptance notice for its clinical research in China.

On November 25, 2024 Adcendo, a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, reported the successful closing of an oversubscribed $135 million Series B financing round (Press release, ADCendo, NOV 25, 2024, View Source [SID1234648597]). Proceeds from the fundraise will be used to advance, broaden, and accelerate the development of the Company’s first-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing round was led by TCGX, with participation from new investors TPG Life Sciences Innovations, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, as well as all existing investors, including RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital.

"We are thrilled with a financing round of this magnitude and the support shown from such a strong group of investors as we continue to advance our pipeline of breakthrough ADCs for the treatment of underserved cancers," said Michael Pehl, Chief Executive Officer of Adcendo. "The excitement in the ADC space paired with our team’s experience and passion for the underlying science motivates us to continue pushing our programs forward into the clinic. We look forward to achieving key milestones across our pipeline with the support of this fundraising."

Cariad Chester, Managing Partner of TCGX, commented: "ADCs have transformed the clinical landscape and standard of care in the treatment of solid tumors. Continued progress for hard-to-treat cancers will require innovative approaches and I’m confident Adcendo will be a leader in the next era of ADC drug development. With this financing, Adcendo can rapidly advance a pipeline of exciting, differentiated ADC candidates. These programs have the potential to significantly change the treatment paradigm in multiple cancers and serve patients in need of better therapies."

As part of the financing, the new Adcendo Board of Directors will consist of John Haurum (Chairman), Cariad Chester (Managing Partner of TCGX), Nandita Shangari (Managing Director at RA Capital), Jeroen Bakker (Partner at Novo Holdings), Carolyn Ng (Business Unit Partner at TPG Life Sciences Innovations), Ohad Hammer (Partner at Pontifax Venture Capital), Iyona Rajkomar (Managing Partner of DawnBio, a platform controlled by KKR) and Michael Pehl (CEO of Adcendo). Roy Amariglio, Principal at Orbimed Advisors, will serve as a board observer.

On November 25, 2024 Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported its participation in the upcoming JMP Securities Hematology and Oncology Summit (Press release, Kura Oncology, NOV 25, 2024, View Source [SID1234648613]). Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 2:00 p.m. ET / 11:00 a.m. PT on December 2, 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available following the live event.

On November 25, 2024 J INTS BIO reported research findings on its innovative brain tumor treatment, ‘JIN-001,’ developed in collaboration with MD Anderson Cancer Center, at the 2024 Society of Neuro-Oncology (SNO) Annual Meeting in Texas, USA. MD Anderson is a globally renowned cancer research institution, and J INTS BIO has partnered with it since 2021 to advance this groundbreaking therapy (Press release, J INTS BIO, NOV 25, 2024, View Source;enhancing-radiation-and-chemotherapy-efficacy-302315138.html [SID1234648629]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JIN-001: Aiming to Revolutionize Brain Tumor Treatment

‘JIN-001’ targets glioblastoma (GBM) cells by significantly enhancing the efficacy of radiation therapy and chemotherapy. As a selective inhibitor of HSP90 (Heat Shock Protein 90), its primary advantage lies in its ability to cross the blood-brain barrier (BBB), which typically hinders therapeutic agents from reaching the brain. While the BBB serves as a protective mechanism for the brain, it also presents a major obstacle for drug delivery. JIN-001 overcomes this limitation, directly attacking brain tumors and addressing the low permeability issue of existing drugs.

The study also highlighted that JIN-001 demonstrated promising results when combined with standard therapies such as Radiation Therapy and Temozolomide, effectively suppressing tumor cell growth and inducing apoptosis (programmed cell death).

JIN-001: Pioneering Future Clinical Developments

Based on these promising findings, J INTS BIO plans to accelerate preclinical trials for JIN-001. The company intends to incorporate CRISPR gene-editing technology to identify the functional roles of specific genetic factors in treatment resistance, paving the way for precision medicine strategies. CRISPR-based techniques allow targeted modulation of gene expression, helping to predict and better understand tumor responses.

J INTS BIO is also advancing plans to commercialize JIN-001 through partnerships with global pharmaceutical companies, aiming to bring faster and more effective treatments to brain tumor patients. Furthermore, the potential applications of JIN-001 are being explored in treating a wide range of cancers beyond brain tumors, providing new hope for cancer patients worldwide.

JIN-001 represents a groundbreaking innovation that transcends the limitations of existing therapies, offering new treatment opportunities and hope for improved survival and quality of life for brain tumor patients.

On November 25, 2024 Alkermes plc (Nasdaq: ALKS) reported that management will participate in two upcoming investor conferences (Press release, Alkermes, NOV 25, 2024, View Source [SID1234648598]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

7th Annual Evercore ISI HealthCONx Conference
Date/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. ET (3:25 p.m. GMT)

Piper Sandler 36th Annual Healthcare Conference
Date/Time: Wednesday, Dec. 4, 2024 at 4:00 p.m. ET (9:00 p.m. GMT)

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.